Browse by author
Lookup NU author(s): Professor Ruth Plummer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited. © 2006 Elsevier Ltd. All rights reserved.
Author(s): Plummer ER
Publication type: Review
Publication status: Published
Journal: Current Opinion in Pharmacology
Print publication date: 01/08/2006
ISSN (print): 1471-4892